Coya Therapeutics’ (COYA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note released on Wednesday morning, Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, HC Wainwright assumed coverage on Coya Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating and a $18.00 target price on the stock.

Coya Therapeutics Stock Down 9.7 %

Shares of COYA stock opened at $6.66 on Wednesday. The company has a market capitalization of $97.28 million, a price-to-earnings ratio of -7.83 and a beta of 0.58. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69. The firm has a fifty day moving average of $6.87 and a 200-day moving average of $7.09.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $3.43 million during the quarter. On average, equities analysts expect that Coya Therapeutics will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Gilbert & Cook Inc. acquired a new position in Coya Therapeutics during the second quarter valued at approximately $61,000. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at approximately $101,000. GHP Investment Advisors Inc. bought a new position in shares of Coya Therapeutics in the third quarter valued at $169,000. Finally, Vanguard Group Inc. increased its holdings in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.